Cargando…
Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas
The variability of tumour responses to chemotherapeutic agents is a topic of major interest in current oncology research. Advances in the knowledge of molecular pathology of cancer make available strategies by which tumour cells can be profiled for their genetic background in order to select antican...
Autores principales: | Loni, L, Tacca, M Del, Danesi, R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363952/ https://www.ncbi.nlm.nih.gov/pubmed/11720423 http://dx.doi.org/10.1054/bjoc.2001.2130 |
Ejemplares similares
-
Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile
por: Giovannetti, E, et al.
Publicado: (2005) -
Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma
por: Veal, Gareth J., et al.
Publicado: (2016) -
Anticancer Drug-Induced Cardiotoxicity: Insights and Pharmacogenetics
por: Adhikari, Archana, et al.
Publicado: (2021) -
Drug Resistance in Non-Hodgkin Lymphomas
por: Klener, Pavel, et al.
Publicado: (2020) -
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)